10-Q: PharmaCyte Biotech Reports Q2 2025 Results, Highlights Investment Gains and Ongoing Clinical Hold Efforts

PharmaCyte Biotech's Q2 2025 report reveals a significant net income driven by investment gains, alongside ongoing efforts to address an FDA clinical hold on their pancreatic cancer therapy.

Summary

• PharmaCyte Biotech reported a net income of $21.95 million for the six months ended October 31, 2024, a significant turnaround from a loss of $393,401 in the same period last year.
• This income was primarily driven by a $21.4 million gain on a related party investment in TNF Pharmaceuticals, Inc.
• The company's cash and cash equivalents decreased from $50.2 million to $20.8 million during the same period.
• Operating expenses decreased to $2.37 million from $3.48 million year-over-year, mainly due to reduced director fees and general and administrative costs.
• The company continues to work on addressing the FDA's clinical hold on their Investigational New Drug Application (IND) for a planned clinical trial in locally advanced pancreatic cancer (LAPC).
• The company has completed several studies requested by the FDA, including stability studies, genetic sequencing, and biocompatibility assessments.
• The company has also made a $7 million investment in TNF Pharmaceuticals, Inc., acquiring preferred stock and warrants.
• The company repurchased 1,003,382 shares of its common stock for $2.17 million during the six-month period.
• The company's working capital decreased from approximately $43 million to $17 million during the period.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company achieved a significant net income due to investment gains, the ongoing clinical hold, cash burn, and uncertainties surrounding the relationship with SG Austria temper the positive aspects. The company's future is highly dependent on resolving the FDA issues and securing additional funding.

Positives

• The company achieved a significant net income of $21.95 million, a substantial improvement from the previous year's loss.
• The gain on the investment in TNF Pharmaceuticals, Inc. indicates a successful strategic investment.
• Operating expenses were reduced by $1.1 million, demonstrating cost management efforts.
• The company has made progress in completing studies required by the FDA to address the clinical hold.
• The company has successfully completed stability studies on its product candidate for pancreatic cancer.
• The company has completed genetic sequencing studies confirming the integrity of the genes used in their therapy.
• The company has completed biocompatibility studies, showing no evidence of toxicity from the capsule material.

Negatives

• The company's cash and cash equivalents decreased significantly from $50.2 million to $20.8 million.
• The company continues to face a clinical hold from the FDA on its IND for LAPC.
• The company's working capital decreased from approximately $43 million to $17 million.
• The company has incurred significant losses in the past, and its ability to raise capital is not assured.
• The company's relationship with SG Austria is under review, which could impact development programs.
• The company has a history of operating losses and liquidity challenges.

Risks

• The company's ability to lift the FDA clinical hold on its IND is uncertain and dependent on completing additional studies and addressing FDA concerns.
• The company's relationship with SG Austria is under review, and a new framework may be required, potentially delaying or terminating development programs.
• The company's history of operating losses and liquidity challenges may make it difficult to raise capital on acceptable terms.
• The company's dependence on third parties for preclinical studies and clinical trials poses a risk.
• The company's product candidates may prove to be unsafe or ineffective.
• The company's ability to obtain and maintain regulatory approval for its product candidates is uncertain.
• The company's ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on the business, financial condition and results of operations.

Future Outlook

The company expects its current cash and cash equivalents of approximately $16 million as of the filing of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly Report. The company may need to raise additional capital in order to initiate and pursue potential additional projects, including the continuing development beyond the ongoing pancreatic cancer research.

Management Comments

• The Board has curtailed spending on the Company's programs, including pre-clinical and clinical activities, until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented.
• The Business Review Committees recommendations will include potentially seeking a new framework for the Company's relationship with SG Austria and its subsidiaries.
• The company is reevaluating those programs which are dependent on SG Austria and the U.S. Food and Drug Administrations (the FDA) acceptance of its technologies, including our development programs for locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC).

Industry Context

The company's focus on cellular therapies for cancer using its Cell-in-a-Box technology aligns with the growing interest in personalized medicine and targeted therapies in the biotechnology industry. The clinical hold on their IND highlights the regulatory challenges faced by companies developing novel therapies. The investment in TNF Pharmaceuticals, Inc. reflects a trend of strategic partnerships and investments within the biotech sector.

Comparison to Industry Standards

• PharmaCyte's financial performance is mixed compared to industry peers. While the company achieved a significant net income due to investment gains, its operating losses and cash burn are concerning.
• Companies like Celldex Therapeutics (CLDX) and Adaptimmune Therapeutics (ADAP) are also focused on developing novel cancer therapies, but they have different financial profiles and clinical development stages.
• Celldex, for example, has a more diversified pipeline and has generated revenue from collaborations, while Adaptimmune is focused on T-cell therapies and has faced challenges in clinical trials.
• PharmaCyte's reliance on a single technology platform and its ongoing issues with the FDA clinical hold are significant risks compared to companies with more diversified portfolios.
• The company's investment in TNF Pharmaceuticals, Inc. is a unique strategy, and its success will depend on the performance of TNF and the terms of the agreement.
• The company's cash burn rate is high, and its ability to raise additional capital is uncertain, which is a common challenge for early-stage biotech companies.

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint against the company for breach of contract, seeking damages of not less than $1,950,000, warrants, and attorneys fees.
• The company intends to vigorously defend against Wainwright's complaint.

Related Party Transactions

• The company owns 13.9% of the equity in SG Austria.
• The company purchased products and services from SG Austria's subsidiaries in the approximate amounts of $0 in the three and six months ended October 31, 2024, and 2023, respectively.
• The company has a consulting agreement with Vin-de-Bona, owned by individuals involved in the company's scientific endeavors.
• The company's Interim Chief Executive Officer serves on the board of directors of Femasys and TNF.

Stakeholder Impact

• Shareholders may be concerned about the decrease in cash and the ongoing clinical hold, but encouraged by the net income and progress on FDA studies.
• Employees may be affected by the curtailment of spending and the uncertainty surrounding the company's future.
• Customers and suppliers may be impacted by the delays in the company's development programs.
• Creditors may be concerned about the company's liquidity and ability to repay debts.

Next Steps

• The company will continue to work on addressing the FDA's clinical hold on their IND for LAPC.
• The company will continue to review its relationship with SG Austria and seek a new framework.
• The company will continue to evaluate its development programs and make recommendations.
• The company will continue to monitor its cash position and explore options for additional funding.

Key Dates

Keywords

PharmaCyte Biotech, Cell-in-a-Box, pancreatic cancer, clinical hold, FDA, biotechnology, investment, TNF Pharmaceuticals, CypCaps, preclinical studies, clinical trials, warrant liability, preferred stock, share repurchase, financial results